Concepedia

Jolene Molter

JM

Statistics

Publications

4

Citations

362

H-Index

4

Active since

2015

Affiliations

Casma Therapeutics (United States)(Current)

Jolene Molter is an author at Casma Therapeutics (United States) specializing in pharmacology, oncology, and molecular oncology.

Publications per year

2015–2020

4

Publications

4

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Siegfried Reich, Paul A. Sprengeler, Gary G. Chiang et al. · Journal of Medicinal Chemistry · 2018 · 177 citations · Full text

, , +17

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Justin T. Ernst, Peggy A. Thompson, Christian Nilewski et al. · Journal of Medicinal Chemistry · 2020 · 145 citations · Full text

, , +16

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Kevin R. Webster, Vikas Goel, Ivy N. Hung et al. · Blood · 2015 · 26 citations

, , +6

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

Peggy A. Thompson, Boreth Eam, Nathan P. Young et al. · Blood · 2017 · 14 citations

, , +5

1–4 of 4